Glipatab 10 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Empagliflozin |
| Company | Ibn sina pharmaceuticals ltd |
| Also available as |
Title
Glipatab 10 mg Tablet
Categories
- Medicine
- Diabetes
- Cardiovascular Disease
- SGLT-2 Inhibitor
Description
Glipatab is a medication used to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Dosage and administration
The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empagliflozin is recommended.
Pharmacology
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Interactions
- Diuretics
- Insulin or Insulin Secretagogues
- Positive Urine Glucose Test
- Interference with 1,5-anhydroglucitol (1,5-AG) Assay
Contraindications
- Serious hypersensitivity reaction to Empagliflozin or any of its ingredients
- Severe renal impairment
- End-stage renal disease
- Dialysis
Side effects
- Urinary tract infections
- Female genital mycotic infections
- Dehydration
- Hypotension
- Weakness
- Dizziness
- Increased thirstiness
Pregnancy and lactation
- Use during pregnancy only if the potential benefit justifies the potential risk to the fetus
- Not recommended when breastfeeding
Precautions and warnings
- Assessment of renal function recommended prior to initiation of Glipatab and periodically thereafter
- Should not be initiated in patients with an eGFR less than 45 ml/min/1.73 m²
- Dose adjustment needed in patients with eGFR greater than or equal to 45 ml/min/1.73 m²
Overdose effects
Supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed in the event of an overdose with Glipatab.
Therapeutic class
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage conditions
Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.
Chemical structure
Molecular Formula: C23H27ClO7
Commonly asked questions
- What is Glipatab 10 mg Tablet?
- What is Glipatab 10 mg Tablet used for?
- Are there any pregnancy warnings?
- Are there any breast-feeding warnings?
- Does this affect kidney function?
- Does this affect liver function?
- Quick Tips